Bokf Na cut its holdings in Eli Lilly And Co (NYSE:LLY) by 5.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 77,644 shares of the company’s stock after selling 4,194 shares during the quarter. Bokf Na’s holdings in Eli Lilly And Co were worth $8,985,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. FDx Advisors Inc. increased its position in shares of Eli Lilly And Co by 48.3% during the fourth quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock worth $2,257,000 after purchasing an additional 6,356 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of Eli Lilly And Co by 3.3% during the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock worth $23,660,000 after purchasing an additional 6,474 shares in the last quarter. Waverton Investment Management Ltd increased its position in shares of Eli Lilly And Co by 1.9% during the fourth quarter. Waverton Investment Management Ltd now owns 12,724 shares of the company’s stock worth $1,472,000 after purchasing an additional 238 shares in the last quarter. Pennsylvania Trust Co increased its position in shares of Eli Lilly And Co by 46.4% during the fourth quarter. Pennsylvania Trust Co now owns 85,021 shares of the company’s stock worth $9,839,000 after purchasing an additional 26,947 shares in the last quarter. Finally, Sumitomo Life Insurance Co. increased its position in shares of Eli Lilly And Co by 2.7% during the fourth quarter. Sumitomo Life Insurance Co. now owns 30,683 shares of the company’s stock worth $3,551,000 after purchasing an additional 800 shares in the last quarter. Institutional investors and hedge funds own 78.69% of the company’s stock.

In other news, SVP Alfonso G. Zulueta sold 4,000 shares of the company’s stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total value of $480,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Enrique A. Conterno sold 25,000 shares of the company’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $121.00, for a total value of $3,025,000.00. The disclosure for this sale can be found here. Insiders have sold 833,190 shares of company stock worth $102,388,102 in the last three months. 0.11% of the stock is currently owned by corporate insiders.

Several brokerages recently commented on LLY. UBS Group began coverage on Eli Lilly And Co in a research report on Wednesday. They set a “buy” rating for the company. Citigroup set a $124.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Tuesday, February 26th. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $121.00 price target for the company in a research report on Wednesday, December 19th. Cantor Fitzgerald reiterated a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Finally, Argus reiterated a “buy” rating on shares of Eli Lilly And Co in a research report on Thursday, December 27th. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Eli Lilly And Co currently has an average rating of “Buy” and a consensus target price of $113.06.

NYSE LLY opened at $128.16 on Thursday. The firm has a market cap of $129.68 billion, a price-to-earnings ratio of 23.09, a P/E/G ratio of 2.52 and a beta of 0.33. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. Eli Lilly And Co has a fifty-two week low of $74.51 and a fifty-two week high of $130.75.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). The company had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the firm posted $1.14 EPS. Equities analysts anticipate that Eli Lilly And Co will post 5.64 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/eli-lilly-and-co-lly-stake-lowered-by-bokf-na/2906034.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What are the benefits of a balanced fund?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.